Exabis Library

Corrigendum:

In the originally published version of this poster presentation, the below corrections have been made.

Upon the original publication, the Results section should read: “250 patients were randomised: 125 to FM and 125 to IV FCM. The primary endpoint was not met. Hb, serum iron and HRQoL all improved following both treatments at Week 12. Improvements in SF-36 physical component summary (PCS) and mental component summary (MCS) scores were slightly greater with FM (difference not statistically significant; Table 1). HRQoL improved across all SF-36 domain scores with both FM and FCM, with no statistically significant differences between treatments (Figure 1). HRQoL (MCS and PCS) improvements were positively associated with increases in Hb and serum iron (Table 1).”.

Upon the original publication, the Conclusion should read: “FM provides HRQoL benefits at least as great as those with IV FCM, and may, therefore, provide an oral alternative to IV iron in patients with IBD.” instead of “FM provides non-inferior efficacy to IV FCM with at least as great a benefit to HRQoL and may, therefore, provide an oral alternative to IV iron in patients with IBD.”.